Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA)

U Schmidt-Erfurth, J Garcia-Arumi, F Bandello, K Berg, U Chakravarthy, BS Gerendas, J Jonas, M Larsen, R Tadayoni, A Loewenstein

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Diabetic retinal disease is envisioned to become the plague of the coming decades with a steep increase of worldwide diabetes incidence followed by a substantial rise in retinal disease. Improvements in diagnostic and therapeutic care have to cope with this dilemma in a clinically and socioeconomically efficient manner. Laser treatment has found a less destructive competitor in pharmacological treatments. As a consequence of recent rigorous clinical trials, laser photocoagulation is no longer recommended for the treatment of diabetic macular edema (DME), and anti-vascular endothelial growth factor therapy has emerged as first-line therapy. Steroids have maintained a role in the management of chronically persistent DME. The paradigm shifts in therapy are accompanied by a substantial break-through in diagnostics. The following guidance for the management of DME has been composed from the best updated knowledge of leading experts in Europe and represents another volume in the series of EURETINA recommendations for the management of retinal disease. © 2017 S. Karger AG, Basel.
Original languageEnglish
Pages (from-to)185-222
Number of pages38
JournalOphthalmologica
Volume237
Issue number4
DOIs
Publication statusPublished - 2017

Fingerprint

Macular Edema
Guidelines
Retinal Diseases
Therapeutics
Lasers
Plague
Light Coagulation
Vascular Endothelial Growth Factor A
Retina
Steroids
Clinical Trials
Pharmacology
Incidence

Cite this

Schmidt-Erfurth, U., Garcia-Arumi, J., Bandello, F., Berg, K., Chakravarthy, U., Gerendas, BS., ... Loewenstein, A. (2017). Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica, 237(4), 185-222. https://doi.org/10.1159/000458539

Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA). / Schmidt-Erfurth, U; Garcia-Arumi, J; Bandello, F; Berg, K; Chakravarthy, U; Gerendas, BS; Jonas, J; Larsen, M; Tadayoni, R; Loewenstein, A.

In: Ophthalmologica, Vol. 237, No. 4, 2017, p. 185-222.

Research output: Contribution to journalArticle

Schmidt-Erfurth, U, Garcia-Arumi, J, Bandello, F, Berg, K, Chakravarthy, U, Gerendas, BS, Jonas, J, Larsen, M, Tadayoni, R & Loewenstein, A 2017, 'Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA)', Ophthalmologica, vol. 237, no. 4, pp. 185-222. https://doi.org/10.1159/000458539
Schmidt-Erfurth, U ; Garcia-Arumi, J ; Bandello, F ; Berg, K ; Chakravarthy, U ; Gerendas, BS ; Jonas, J ; Larsen, M ; Tadayoni, R ; Loewenstein, A. / Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA). In: Ophthalmologica. 2017 ; Vol. 237, No. 4. pp. 185-222.
@article{ce78bbbfebc949f1b90b5d2be3fd7520,
title = "Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA)",
abstract = "Diabetic retinal disease is envisioned to become the plague of the coming decades with a steep increase of worldwide diabetes incidence followed by a substantial rise in retinal disease. Improvements in diagnostic and therapeutic care have to cope with this dilemma in a clinically and socioeconomically efficient manner. Laser treatment has found a less destructive competitor in pharmacological treatments. As a consequence of recent rigorous clinical trials, laser photocoagulation is no longer recommended for the treatment of diabetic macular edema (DME), and anti-vascular endothelial growth factor therapy has emerged as first-line therapy. Steroids have maintained a role in the management of chronically persistent DME. The paradigm shifts in therapy are accompanied by a substantial break-through in diagnostics. The following guidance for the management of DME has been composed from the best updated knowledge of leading experts in Europe and represents another volume in the series of EURETINA recommendations for the management of retinal disease. {\circledC} 2017 S. Karger AG, Basel.",
author = "U Schmidt-Erfurth and J Garcia-Arumi and F Bandello and K Berg and U Chakravarthy and BS Gerendas and J Jonas and M Larsen and R Tadayoni and A Loewenstein",
year = "2017",
doi = "10.1159/000458539",
language = "English",
volume = "237",
pages = "185--222",
journal = "Ophthalmologica",
issn = "0030-3755",
publisher = "S. Karger AG",
number = "4",

}

TY - JOUR

T1 - Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA)

AU - Schmidt-Erfurth, U

AU - Garcia-Arumi, J

AU - Bandello, F

AU - Berg, K

AU - Chakravarthy, U

AU - Gerendas, BS

AU - Jonas, J

AU - Larsen, M

AU - Tadayoni, R

AU - Loewenstein, A

PY - 2017

Y1 - 2017

N2 - Diabetic retinal disease is envisioned to become the plague of the coming decades with a steep increase of worldwide diabetes incidence followed by a substantial rise in retinal disease. Improvements in diagnostic and therapeutic care have to cope with this dilemma in a clinically and socioeconomically efficient manner. Laser treatment has found a less destructive competitor in pharmacological treatments. As a consequence of recent rigorous clinical trials, laser photocoagulation is no longer recommended for the treatment of diabetic macular edema (DME), and anti-vascular endothelial growth factor therapy has emerged as first-line therapy. Steroids have maintained a role in the management of chronically persistent DME. The paradigm shifts in therapy are accompanied by a substantial break-through in diagnostics. The following guidance for the management of DME has been composed from the best updated knowledge of leading experts in Europe and represents another volume in the series of EURETINA recommendations for the management of retinal disease. © 2017 S. Karger AG, Basel.

AB - Diabetic retinal disease is envisioned to become the plague of the coming decades with a steep increase of worldwide diabetes incidence followed by a substantial rise in retinal disease. Improvements in diagnostic and therapeutic care have to cope with this dilemma in a clinically and socioeconomically efficient manner. Laser treatment has found a less destructive competitor in pharmacological treatments. As a consequence of recent rigorous clinical trials, laser photocoagulation is no longer recommended for the treatment of diabetic macular edema (DME), and anti-vascular endothelial growth factor therapy has emerged as first-line therapy. Steroids have maintained a role in the management of chronically persistent DME. The paradigm shifts in therapy are accompanied by a substantial break-through in diagnostics. The following guidance for the management of DME has been composed from the best updated knowledge of leading experts in Europe and represents another volume in the series of EURETINA recommendations for the management of retinal disease. © 2017 S. Karger AG, Basel.

U2 - 10.1159/000458539

DO - 10.1159/000458539

M3 - Article

VL - 237

SP - 185

EP - 222

JO - Ophthalmologica

JF - Ophthalmologica

SN - 0030-3755

IS - 4

ER -